The estimated Net Worth of Brian Roman is at least $1.7 million dollars as of 28 May 2024. Mr Roman owns over 89,419 units of Viatris stock worth over $767,979 and over the last 4 years he sold VTRS stock worth over $928,169.
Mr has made over 4 trades of the Viatris stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 89,419 units of VTRS stock worth $928,169 on 28 May 2024.
The largest trade he's ever made was exercising 120,525 units of Viatris stock on 2 March 2024 worth over $1,366,754. On average, Mr trades about 28,354 units every 91 days since 2021. As of 28 May 2024 he still owns at least 67,723 units of Viatris stock.
You can see the complete history of Mr Roman stock trades at the bottom of the page.
Brian S. Roman is the Global Gen. Counsel at Viatris.
Mr Roman is 51, he's been the Global Gen. Counsel of Viatris since . There are 7 older and 6 younger executives at Viatris. The oldest executive at Viatris Inc. is Sanjeev Narula, 60, who is the Chief Financial Officer.
Brian's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.
Over the last 4 years, insiders at Viatris have traded over $17,988,707 worth of Viatris stock and bought 85,788 units worth $1,086,462 . The most active insiders traders include Ian C Read, James M Kilts et Robert J Coury. On average, Viatris executives and independent directors trade stock every 13 days with the average trade being worth of $708,761. The most recent stock trade was executed by Rajiv Malik on 28 August 2024, trading 100,000 units of VTRS stock currently worth $1,195,000.
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
Viatris executives and other stock owners filed with the SEC include: